肿瘤细胞治疗研究
英文原题：Mapping the research landscape of nanotechnology based immunotherapy for hepatocellular carcinoma.
基于纳米技术的免疫治疗领域已从基础纳米颗粒开发（2005–2009）发展到免疫微环境调控（2010–2018），如今迈入基于mRNA的精准免疫治疗（2019–2024）。未来的努力可能优先考虑整合代谢调控和AI优化递送的综合纳米免疫治疗。
纳米技术的进步为靶向肝细胞癌（HCC）的免疫治疗引入了新方法。本研究旨在通过文献计量分析绘制知识图谱并识别该领域的潜在研究热点。
2005年至2024年关于利用纳米技术的HCC免疫治疗出版物取自Web of Science核心合集（WoSCC）。数据可视化和统计分析主要使用VOSviewer、CiteSpace、R软件和Microsoft Office Excel 2021进行。
系统检索最初从WoSCC中检索到600篇出版物，其中10篇在筛选过程中被排除，最终获得590篇关于纳米技术在HCC免疫治疗中应用的出版物。值得注意的是，年度发文量从2020年的44篇激增至2024年的159篇，在这四年期间增长了261%。中国在发文量和国际合作方面位居首位，尽管其文章的平均被引次数相对较少。美国发文量排名第二，但平均被引次数最高。参考文献的时间线可视化揭示了三个不同阶段（2005–2009年、2010–2018年和2019–2024年），包含以下七个参考文献聚类：#0 cancer chitosan nanoparticle、#1 hepatocellular carcinoma、#2 antigen presentation、#3 carbon nanotube、#4 targeting PD-L1 expression、#5 natural killer cell和#6 liver metastases。“Cancer microenvironment”、“drug delivery”、“immunogenic cell death”和“combination therapy”显示出极高的出现频率。“mRNA”、“mRNA delivery”、“metabolism”是近期涌现的关键词。
BACKGROUND: Advances in nanotechnology have introduced novel methodologies for immunotherapy targeting hepatocellular carcinoma (HCC). This study aims to develop a knowledge map and identify potential research hotspots in this field through bibliometric analysis. METHODS: Publications on HCC immunotherapy utilizing nanotechnology from 2005 to 2024 were obtained from the Web of Science Core Collection (WoSCC). Data visualization and statistical analysis were primarily conducted using VOSviewer, CiteSpace, R software, and Microsoft Office Excel 2021. RESULTS: The systematic search initially retrieved 600 publications from WoSCC, of which 10 were excluded during screening, yielding 590 publications on nanotechnology applications in HCC immunotherapy. Notably, the annual publication count surged from 44 papers in 2020 to 159 papers in 2024, representing an impressive 261% increase over this four-year period. China emerged as the foremost country in publishing volume and international collaborations, although its articles receive relatively few average citations. The USA, ranking second in output, achieves the highest average citation count. The timeline visualization of reference reveals three distinct phases (2005–2009, 2010–2018, and 2019–2024) with the following seven reference clusters: #0 cancer chitosan nanoparticle, #1 hepatocellular carcinoma, #2 antigen presentation, #3 carbon nanotube, #4 targeting PD-L1 expression, #5 natural killer cell, and #6 liver metastases. “Cancer microenvironment”, “drug delivery”, “immunogenic cell death”, and “combination therapy” showed extremely high occurrence frequencies. “mRNA”, “mRNA delivery”, “metabolism” were the key keywords that have emerged recently. CONCLUSION: Nanotechnology-based immunotherapy field has evolved from foundational nanoparticle development (2005–2009) to immune microenvironment modulation (2010–2018) and now embraces mRNA-based precision immunotherapy (2019–2024). Future efforts may prioritize combinatorial nano-immunotherapies integrating metabolic regulation and AI-optimized delivery.
MEMBER ACCOUNT
登录成功会直接打开下一页。
